TATVA Share Price Performance
₹0
-832.55 (-100.00%)
Price ₹0
Fair Value₹1,200.00
Share Pricen/a
Tatva Chintan Pharma Chem Limited Just Beat EPS By 6.0%: Here's What Analysts Think Will Happen Next
Nov 05
Tatva Chintan Pharma Chem Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
TATVA Community Narratives
AN
Fair Value ₹1.2k 24.1% overvalued intrinsic discount
Eco-friendly Specialty Chemicals Will Drive Global Market Expansion
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹535 178.4% overvalued intrinsic discount
Rising ESG Pressures And Localization Will Erode Export Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹1.04k 43.9% overvalued intrinsic discount
Overvaluation Risks And Emerging Sectors Will Shape Future Dynamics
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Overvaluation Risks And Emerging Sectors Will Shape Future Dynamics
Key Takeaways Tighter environmental standards and rising protectionism could restrict market access, increase compliance costs, and slow export-driven growth. Lagging in advanced green chemistry and relying on few large customers amplifies both innovation risks and earnings volatility.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
₹1.04k
43.9% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
22.89% p.a.
Profit Margin
14.96%
Future PE
30.01x
Share price in 2028
₹1.45k
Eco-friendly Specialty Chemicals Will Drive Global Market Expansion
Key Takeaways Early capacity gains, accelerated customer onboarding, and niche leadership position Tatva Chintan for significant earnings and cash flow growth beyond market forecasts. Direct export relationships and a focus on green, high-margin specialty chemicals provide enduring pricing power and long-term revenue upside amid global supply shifts.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹1.2k
24.1% overvalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
23.02% p.a.
Profit Margin
14.51%
Future PE
41.26x
Share price in 2028
₹1.75k
Rising ESG Pressures And Localization Will Erode Export Outlook
Key Takeaways Escalating regulatory, cost, and localization pressures threaten profitability and market access for Tatva Chintan's export-centric business model. Heavy dependence on core chemical products and rising global competition expose the company to earnings volatility and weakened industry positioning.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹535
178.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
20.9% p.a.
Profit Margin
7.67%
Future PE
36.61x
Share price in 2028
₹780.03
Snowflake Analysis
Tatva Chintan Pharma Chem Limited Key Details
About TATVA
- Founded
- 1996
- Employees
- 679
- CEO
- WebsiteView website
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
